Arix Bioscience PLC (LON:ARIX) announced that its portfolio company Autolus Therapeutics has received the green light for AUTO1, its lead candidate for the treatment of lymphoblastic leukaemia.
The approval by the US Food and Drug Administration allows the first study on AUTO1 to begin.
READ: Arix Bioscience shuffles board, names Naseem Amin as executive chairman with immediate effect
Arix, an investor in breakthrough biotech companies, said the clinical study will suffer “minimal” impact from the coronavirus outbreak.
It said Autolus also continues to manufacture from its operations at the UK Cell and Gene Therapy Catapult, including supply to the US of clinical products for a study on the treatment of Diffuse Large B-cell Lymphoma.
Shares rose 2% to 83.88p on Friday afternoon.